Synthetic Biology Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2023Facts of WeekSynthetic Biology Market analysis is provided for global market including development trends by regions, competitive analysi… Continue reading
Endpoints News |
Bioverativ inks $100M gene therapy deal with Oxford BioMedica
Endpoints News But thanks to Spark Therapeutics, which got the FDA OK to treat blindness with gene therapy drug Luxturna late last year, the entire field is now coming of age. And now Oxford BioMedica is cashing in. The new deal will get Bioverativ access to Oxford’s … Oxford BioMedica wins second $100 million gene therapy contractReuters Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene TherapyGenetic Engineering & Biotechnology News Oxford BioMedica share price rises on $100m gene therapy deal with BioverativCity A.M. Interactive Investor –The Daily Telescope –Stock Market Wire all 11 news articles » |